All In Biotech

Drug Trial Radar · NCT04460352

Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

NEoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed (NEEDS Trial)

Last checked: Nov 19, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,020 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,020

Planned (sponsor's estimate)

Start

Nov 27, 2020

Primary completion

Dec 31, 2026

Study completion Dec 31, 2031

Sponsor

Lead sponsor
Karolinska University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Leipzig; The Swedish Research Council
First posted
Jul 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

NEEDS is a pragmatic open-label, randomised, controlled, phase III, multicenter trial with non-inferiority design with regard to the first co-primary endpoint overall survival and superiority for the experimental intervention definitive chemoradiotherapy. A second co-primary endpoint is global health related quality of life (HRQOL) one year after randomisation. A third co-primary endpoint is eating restictions one year after randomisation. The aim is to compare outcomes after neoadjuvant chemoradiotherapy with subsequent esophagectomy to definitive chemoradiotherapy with surveillance and salvage esophagectomy as needed in patients with resectable locally advanced squamous cell carcinoma (SCC) of the esophagus, with the aim to provide generalisable guidance for future clinical practice.

Conditions

  • Esophageal Squamous Cell Carcinoma

Interventions

  • Neoadjuvant radiotherapy (arm A)Radiation

    1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.

  • Carboplatin, paclitaxelDrug

    Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting same day as radiotherapy

  • EsophagectomyProcedure

    Esophagectomy performed within 8 weeks after termination of chemoradiotherapy

  • Neoadjuvant radiotherapy (arm B)Radiation

    Two alternative schemes: 1. 1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy. 2. 2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy.

  • Carboplatin, paclitaxelDrug

    Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy (5 weeks or 6 weeks, depending on the radiotherapy regimen used).

  • Cisplatin, paclitaxelDrug

    Cisplatin 75mg/m2 on the first day of weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion on the first four days of weeks 1 and 5.

  • Oxaliplatin, calcium folinate, 5-fluorouracilDrug

    FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 on the first days of weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion on the first two days of weeks 1, 3 and 5.

  • EsophagectomyProcedure

    Esophagectomy only in case of residual or recurrent locoregional cancer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: 3 years after randomisation
  2. Global Health-related quality of life (HRQOL)Time frame: 1 year after randomisation
  3. Eating restrictionsTime frame: 1 year after randomisation

Locations

12 sites in 5 countries. Site status is shown where the registry gives one.

  • McGill University Health Centre

    Montreal, Quebec, Canada · Recruiting

  • Cancer Clinical Trials Unit (CCTU) at St. James's Hospital

    Dublin, Dublin, Ireland · Recruiting

  • Oslo universitetssykehus

    Oslo, Norway · Recruiting

  • Universitetssykehuset Nord-Norge

    Tromsø, Norway · Recruiting

  • St Olavs Hospital

    Trondheim, Norway · Recruiting

  • Linköpings universitetssjukhus

    Linköping, Sweden · Recruiting

  • Skånes universitetssjukhus

    Lund, Sweden · Recruiting

  • Örebro universitetssjukhus

    Örebro, Sweden · Recruiting

  • Karolinska University Hospital

    Stockholm, Sweden · Recruiting

  • Norrlands universitetssjukhus

    Umeå, Sweden · Recruiting

  • Akademiska sjukhuset

    Uppsala, Sweden · Recruiting

  • Chang Gung Memorial Hospital

    Linkou District, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.